Recent high-profile drug withdrawals have heightened scrutiny of medication safety. Accordingly, regulatory authorities now expect manufacturers to develop proactive strategies for assessing and minimizing risk. PharmaNet Consulting professionals can help you better understand risk management and formulate a successful strategy covering every stage of development from early planning to post-marketing.
PharmaNet professionals available for consultation on this topic include:
Vice President, Clinical Research, Phase IV Development
Jan Willem van der Velden, MD, FFPM
Senior Vice President, Global Safety and Pharmacovigilance
504 Carnegie Center, Princeton, NJ 08540